focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.35
Bid: 5.80
Ask: 5.85
Change: 0.175 (3.10%)
Spread: 0.05 (0.862%)
Open: 5.50
High: 5.95
Low: 5.35
Prev. Close: 5.65
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Technology Update

6 Jun 2017 07:00

RNS Number : 2009H
Plant Health Care PLC
06 June 2017
 

6 June 2017

Plant Health Care plc(the "Company" ", "PHC" or "Plant Health Care")New Technology Update

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

- Evaluation of Innatus 3G continues to expand. The four major industry partners have increased the scale of their 2017 trials. Three other companies have signed evaluation agreements and are conducting field trials.

- A total of eight agreements have also now been signed concerning T-Rex 3G and Y-Max-3G.

- Strong progress continues within Plant Health Care on its capability to make, formulate and register PREtec peptides.

- The Company remains on track to deliver a revenue-generating licence by the end of 2017 and the first competitive licensing process in early 2018.

 

Innatus 3G

Four of the top six agrochemicals companies have been evaluating Innatus 3G since 2015. They are focused on three core agricultural benefits - yield increase, disease and nematode protection and drought resistance - mainly in the largest commercial crops corn (maize) and soybean. Building on their 2016 results, all are running trials of lead peptides from this platform in 2017.

By early 2017, three other companies had signed agreements to evaluate Innatus 3G. Their field trials, in other smaller crops, are underway in Europe and South America.

In recent weeks several partners have approached PHC with plans to expand their 2017 trials further. Of particular interest is the control of Asian Soybean Rust, a fungal disease which is a major threat to the soybean crop in Brazil. This disease has developed resistance to most conventional fungicides. Innatus 3G peptides work very differently, and when sprayed in mixtures with standard fungicides, they have shown significantly improved disease control in PHC's trials. This has the potential to increase the effectiveness and extend the commercial life of those established products.

T-Rex 3G and Y-Max 3G

PHC's new technology platforms, T-Rex 3G and Y-Max 3G, were first presented to the industry in 2016. T-Rex 3G is a class of signal peptides optimised for nematode suppression, while Y-Max 3G peptides are biostimulants which increase yield.

A total of eight companies have so far signed up to evaluate one or both of these new platforms, including the majors who are evaluating Innatus 3G. Trials are in progress in three continents in a range of crops, with two lead peptides from each of T-Rex 3G and Y-Max 3G. The majors are focused mainly on corn and soybean, while others are working on a wider range of crops.

The Company continues to aim to secure the first revenue-generating licence of one of its PREtec technologies in 2017.

PHC's product development capability

Plant Health Care has increased its product development activity. This includes substantially expanding its own 2017 field trials and contract testing programme. But because partners' evaluations of PREtec peptides are on a much larger scale than in 2016, collectively they are spending many times more than the Company is.

Plant Health Care's work on the physical stability of peptides in formulations and their compatibility with agrochemicals continues to show promising results. We expect the most cost-effective means of peptide manufacture to be by fermentation, and laboratory scale production trials are on track. The first lead peptides produced by fermentation are being evaluated and will shortly be entering field trials.

 

Chris Richards, Executive Chairman & Interim CEO, said "Momentum continues to build. As we approach the expected 2018 date for licensing of first rights to Innatus 3G, partners are stepping up their evaluations. Our lead peptides from each platform are performing well in independent trials, carried out by our partners."

"It is a great vote of confidence in our proprietary technology. Every one of our initial partners is now testing one or both of T-Rex 3G and Y-Max 3G, alongside Innatus 3G. Our new partners are expanding the range of crops to which our products can bring benefits. This year, partners will spend much more than us on evaluating our proprietary technology."

"We are well positioned for the first licensing of our PREtec technology by the end of 2017, with competitive licensing of Innatus 3G to start in early 2018."

 

Enquiries:

Plant Health Care plc

Dr Chris Richards, Executive Chairman and Interim CEO

Tel: +44 (0) 18 3788 0083

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke

Tel: +44 (0) 20 3100 2000

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESUGUWCQUPMGMA
Date   Source Headline
10th Nov 20095:29 pmRNSAdditional Listing
6th Nov 200912:53 pmRNSAdditional Listing
4th Nov 20091:52 pmRNSAdditional Listing
2nd Nov 20091:29 pmRNSTotal Voting Rights
1st Oct 20094:21 pmRNSTotal Voting Rights
30th Sep 20095:31 pmRNSDirector/PDMR Shareholding
28th Sep 20096:21 pmRNSAdditional Listing
21st Sep 20099:47 amRNSPosting of Interim Results
21st Sep 20099:41 amRNSAdditional Listing
17th Sep 20096:01 pmRNSAdditional Listing
17th Sep 20095:06 pmRNSAdditional Listing
14th Sep 20097:05 amRNSSustainability Commendation
14th Sep 20097:00 amRNSInterim Results
9th Sep 20097:30 amRNSNotice of Results
1st Sep 200910:19 amRNSTotal Voting Rights
20th Aug 20092:58 pmRNSAdditional Listing
17th Aug 20097:00 amRNSExpansion of Partnership with Scotts
13th Aug 200912:55 pmRNSAdditional Listing
3rd Aug 200910:17 amRNSTotal Voting Rights
28th Jul 20093:05 pmRNSReplacement: Holding(s) in Company
28th Jul 200911:24 amRNSHolding(s) in Company
17th Jul 20091:39 pmRNSAdditional Listing
14th Jul 200912:59 pmRNSDirector/PDMR Shareholding
1st Jul 20097:01 amRNSRe: Monsanto announcement
1st Jul 20097:00 amRNSTotal Voting Rights
25th Jun 20097:00 amRNSSustainable Business 20
9th Jun 20098:35 amRNSDirector/PDMR Shareholding
5th Jun 200910:46 amRNSResult of AGM
4th Jun 20097:00 amRNSTechnical Presentation
3rd Jun 20099:17 amRNSSignificant Shareholding
2nd Jun 20097:00 amRNSMonsanto Order
1st Jun 200911:37 amRNSTotal Voting Rights
1st Jun 20097:00 amRNSEuropean Patent Granted for Harpin
28th May 20095:51 pmRNSAdditional Listing
28th May 20095:23 pmRNSSignificant Shareholding
28th May 20098:47 amRNSHolding(s) in Company
20th May 20099:30 amRNSAdditional Listing
19th May 20098:00 amRNSTest results
18th May 20093:47 pmRNSDirector/PDMR Shareholding
18th May 200910:44 amRNSAdditional Listing
13th May 20091:15 pmRNSDirector/PDMR Shareholding
12th May 200911:53 amRNSEGM Statement
30th Apr 200912:41 pmRNSDirector/PDMR Shareholding
24th Apr 200911:50 amRNSPlacing Announcement
16th Apr 20095:01 pmRNSAnnual Financial Report
15th Apr 20095:20 pmRNSAdditional Listing
2nd Apr 20095:47 pmRNSMonsanto Order
1st Apr 20093:40 pmRNSAdditional Listing
30th Mar 20097:00 amRNSDirector/PDMR Shareholding
24th Mar 200910:49 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.